Table 3

Metabolic and Hormonal Results Before and After 3 Months of Testosterone Supplementation Therapy

Testosterone Group (n = 31)Placebo Group (n = 33)Changes (Δ)
BeforeAfterBeforeAfterTestosteronePlacebo
Fasting glycemia, mg/dl114.8 ± 37.1119.2 ± 33.5111 ± 37.3116 ± 41.34.4 ± 1.35.2 ± 2.0
Fasting insulinemia, μU/ml10.4 ± 2.07.9 ± 1.411.0 ± 3.110.8 ± 2.8−2.5 ± 0.7−0.2 ± 0.1
HOMA-IR2.6 ± 1.41.8 ± 0.82.5 ± 1.12.6 ± 1.0−0.8 ± 0.020.1 ± 0.06
Total cholesterol, mg/dl142.5 ± 43.7148.5 ± 39.3147.3 ± 54.2150.6 ± 67.33.0 ± 1.43.2 ± 1.3
HDL cholesterol, mg/dl36.3 ± 7.136.0 ± 5.737.0 ± 6.236.6 ± 6.9−0.3 ± 0.05−0.4 ± 0.02
Triglycerides, mg/dl131.2 ± 39.7142.5 ± 44.1138.6 ± 32.5135.2 ± 38.111.7 ± 4.3−3.2. ± 1.5
Total testosterone, ng/ml2.3 ± 1.85.2 ± 2.22.1 ± 2.12.3 ± 1.72.9 ± 0.60.2 ± 0.1
Free testosterone, pg/ml11.3 ± 5.632.0 ± 11.212.1 ± 6.012.4 ± 5.721.3 ± 6.40.3 ± 0.2
Total PSA, ng/ml1.4 ± 1.11.5 ± 1.01.3 ± 0.71.4 ± 0.50.1 ± 0.020.1 ± 0.04
Free PSA, ng/ml0.4 ± 0.20.6 ± 0.30.4 ± 0.10.5 ± 0.10.2 ± 0.040.1 ± 0.03
C-reactive protein, mg/dl0.3 ± 0.20.3 ± 0.20.4 ± 0.20.3 ± 0.10.3 ± 0.02−0.1 ± 0.02
Creatinine, mg/dl1.4 ± 0.41.5 ± 0.31.4 ± 0.51.4 ± 0.30.1. ± 0.030.07 ± 0.01

Data are expressed as mean ± SD.

HDL = high-density lipoprotein; HOMA-IR = homeostasis model assessment (21); PSA = prostate-specific antigen.

  • Within groups differences;

  • between groups differences at p < 0.05.